Comparative Pharmacology
Head-to-head clinical analysis: BEEPEN VK versus BICILLIN L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEEPEN VK versus BICILLIN L A.
BEEPEN-VK vs BICILLIN L-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V potassium is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). This disrupts the cross-linking of peptidoglycan chains, leading to cell lysis and death. It is bactericidal against susceptible organisms.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections; maximum 4 g/day.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
None Documented
None Documented
Terminal elimination half-life is 0.7-1.4 hours in patients with normal renal function; prolonged to 3-20 hours in severe renal impairment (CrCl <10 mL/min).
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
Primarily renal (70-80% as unchanged drug), with minor biliary/fecal excretion. Renal clearance is via tubular secretion and glomerular filtration.
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic